Furthermore, inhibition of ROS reversed the chemotherapy-sensitizing effect mediated by SPAG5. Together, these findings suggest that SPAG5 may serve as a promising biomarker and therapeutic target to potentiate the cytotoxic effects of chemotherapy in LACRC patients.

P2, N=99, Recruiting, Mayo Clinic | Trial completion date: Nov 2026 --> May 2031 | Trial primary completion date: May 2026 --> May 2031

P2, N=236, Not yet recruiting, Sixth Affiliated Hospital, Sun Yat-sen University | Trial completion date: Nov 2030 --> Mar 2031 | Initiation date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2027 --> Mar 2031

as exemplified in this case. Consistent data collection, collaboration, and molecular characterization are essential to establish evidence-based treatment strategies for this uncommon malignancy.

In this phase II trial, raltitrexed did not show significant response rates in patients with advanced CRC. Due to limited ORR of raltitrexed, value of TS expression as a biomarker was inconclusive. No new safety signals for raltitrexed were demonstrated.

Missense mutations were the predominant alteration type across groups. These findings suggest that TP53 pathway alterations may be associated with ancestry- and treatment-specific clinical patterns in EOCRC and illustrate how AI-enabled integrative analytic frameworks can facilitate hypothesis generation and prioritize candidate biomarkers for future validation in precision oncology.

In selected fit patients, modified FOLFIRINOX may address mixed phenotypes...Research priorities include ampulla-enriched umbrella trials, explicit AC subcohorts in tissue-agnostic studies, and ctDNA-informed endpoints. This lineage-first, mutation-fast paradigm supports precision care and evidence generation in AC.

Therefore, our results establish GSDMA as a critical downstream mediator of RBM47-induced tumor suppression that links epithelial differentiation and pyroptosis to chemotherapy sensitivity. Finally, these findings identify the RBM47/GSDMA axis as a potential predictive biomarker for the response to Oxaliplatin in CRC patients.

P2, N=364, Active, not recruiting, Kyungpook National University Hospital | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> Dec 2031 | Trial primary completion date: Jun 2025 --> Dec 2028

P3, N=708, Active, not recruiting, Kyungpook National University Hospital | Trial completion date: Dec 2030 --> Dec 2031 | Trial primary completion date: Dec 2024 --> Dec 2028

Neoadjuvant SBRT achieves oncologic outcomes comparable to CFRT in BR/LA PC and is associated with greater adjuvant therapy use. A potential survival signal for SBRT in patients receiving FOLFIRINOX with CA19-9 > 1500U/mL is hypothesis-generating and warrants validation and formal interaction testing.

P3, N=254, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Sep 2030 --> Jun 2031 | Trial primary completion date: Sep 2027 --> Jun 2028